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Abstract
Tetralogy of Fallot (ToF) is the most common type of cyanotic congenital
heart disease. Since the first surgical repair in 1954, treatment has
continuously improved. The treatment strategies currently used in the
treatment of ToF result in excellent long-term survival (30 year survival
ranges from 68.5% to 90.5%). However, residual problems such as right
ventricular outflow tract obstruction, pulmonary regurgitation, and
(ventricular) arrhythmia are common and often require re-interventions.
Right ventricular dysfunction can be seen following longstanding pulmonary
regurgitation and/or stenosis. Performing pulmonary valve replacement or
relief of pulmonary stenosis before irreversible right ventricular dysfunction
occurs is important, but determining the optimal timing of pulmonary valve
replacement is challenging for several reasons. The biological mechanisms
underlying dysfunction of the right ventricle as seen in longstanding
pulmonary regurgitation are poorly understood. Different methods of
assessing the right ventricle are used to predict impending dysfunction. The
atrioventricular, ventriculo-arterial and interventricular interactions of the
right ventricle play an important role in right ventricle performance, but are
not fully elucidated. In this review we present a brief overview of the history
of ToF, describe the treatment strategies currently used, and outline the
long-term survival, residual lesions, and re-interventions following repair.
We discuss important remaining challenges and present the current state of
the art regarding these challenges.
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Introduction
Tetralogy of Fallot (ToF), the most common type of cyan-
otic congenital heart disease (CHD), has an incidence of 0.34 
per 1000 live births1. The classic tetrad (Figure 1) was first 
described in 1673 by bishop and anatomist Nicolas Steno, but 
the anatomy was more extensively described by the French 
physician Étienne-Louis Fallot in 18882,3. Patients with ToF have 
varying degrees of cyanosis depending on the severity of right 
ventricular outflow tract (RVOT) stenosis and pulmonary 
artery (PA) anatomy. The anatomic abnormalities seen in ToF 
vary from milder to more severe phenotypes, such as ToF with 
pulmonary atresia and Fallot-type double outlet right 
ventricle (RV). These more severe forms may require different 
management and treatment strategies. This review focuses on the 
“classic” ToF, with right ventricular outflow (pulmonary) stenosis, 
rather than atresia, and excluding double outlet right ventricle.
Surgical approaches to repair
Surgical repair of ToF was first described in 1955 by Lillehei 
et al.5. The right ventricular outflow tract obstruction (RVOTO) 
was approached by a ventriculotomy into the right ventricular 
anterior wall and relief included inserting a transannular patch 
(TAP) if required (Figure 2, left). Aggressive RVOTO relief 
was advocated as initial results had demonstrated that resid-
ual RVOTO was predictive of early mortality6. This approach 
resulted in relatively good long-term survival7. However, residual 
lesions after repair were common and follow-up studies of these 
first operations showed that these residual lesions resulted in 
late morbidity and mortality8–11. Pulmonary regurgitation (PR) 
was reported in the majority of patients, more commonly in 
those with TAPs12. PR initially was thought to be a relatively 
benign hemodynamic residual lesion but subsequently was 
found to be predictive of decreased exercise performance and 
progressive RV dilation. RV dilation, in turn, was associated 
with ventricular arrhythmia and biventricular dysfunction13–15. 
Furthermore, patients were noted to be at higher risk of 
sudden cardiac death8,9,11,16,17.
Different surgical techniques were developed minimizing 
the extent of the ventriculotomy and trying to preserve com-
petence of the pulmonary valve without causing significant 
residual RVOTO. Via a transatrial or transatrial-transpulmonary 
approach, the need for a ventriculotomy can be reduced (Figure 2, 
right). The transatrial or transatrial-transpulmonary approach 
Figure 1. Schematic overview of the defects seen in tetralogy of 
Fallot. (1) Pulmonary stenosis. (2) Overriding aorta. (3) Malalignment 
ventricular septal defect. (4) Right ventricular hypertrophy. Modified 
from Englert et al.4 with permission from the publisher.
Figure 2. Transventricular (left) and transatrial-transpulmonary (right) approach to tetralogy of Fallot (ToF) repair. VSD, ventricular 
septal defect. Adapted from Bushman18 with permission from the publisher.
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is currently employed in most centers, and the long-term results 
are excellent12,19–22. In patients with a small pulmonary valve 
annulus, a TAP is still necessary for adequate RVOTO relief. 
Other techniques to preserve or replace pulmonary valve 
competence include pulmonary valvuloplasty with patching 
limited to the infundibulum23,24, implantation of a monocusp 
valve25,26, a valved RV-to-PA conduit27,28, or a homograft 
valve27. A survival benefit of these valve-sparing or valve-replacing 
techniques has not yet been demonstrated29–32.
Variations in current treatment strategies
In general, it is thought that earlier primary repair of ToF can 
limit prolonged exposure to RV pressure loading and reduced 
oxygen saturations, preserving cardiovascular33 and brain34 
function. However, there is no consensus on the definition 
of “early” versus later repair. Neonatal repair (that is, repair 
before 1 month of age) is feasible with acceptable results but 
is not widely used and this is because of better short-term 
outcomes of non-neonatal repair35. Neonatal repair more often 
requires TAP compared with repair beyond the neonatal period, 
resulting in worse event-free survival35. In the majority of 
patients, primary repair can be postponed to 3 to 6 months of 
age with excellent outcomes36,37.
Symptomatic ToF patients may require an intervention in 
the neonatal period. Different strategies can be used if pri-
mary repair is judged not to be the best option. Historically, a 
systemic-to-pulmonary shunt—typically a modified Blalock- 
Taussig (mBT) shunt—has been used to increase pulmonary 
flow, reduce hypoxemia, and allow time for PA growth. This 
allows repair to be performed at an older age and has the poten-
tial advantage of using no, or less extensive, TAP. However, 
palliative shunt procedures are associated with a 3% to 5% early 
mortality rate38,39. The superiority of a staged approach versus 
primary neonatal repair has not been demonstrated40,41.
Stenting of the ductus arteriosus (DA) is another strategy to war-
rant pulmonary blood flow after birth by inducing a systemic- 
to-pulmonary shunt. However, in cyanotic CHD, the anatomy 
of the DA might be complex and unsuited for stenting42. 
Procedural success is estimated to be 83%43. Recently published 
multicenter studies compared outcomes following DA stenting 
and mBT shunting using propensity score–adjusted models43,44. 
Clinical status, assessed by saturation, hemoglobin levels, and 
PA size, was more favorable following DA stenting compared 
with mBT shunting43,44. Bentham et al. found better survival 
(hazard ratio 0.25, 95% confidence interval (CI) 0.07–0.85) for 
DA stent compared with mBT43, whereas Glatz et al. found no 
difference in survival (hazard ratio 0.64, 95% CI 0.28–1.47)44. 
A trend toward higher re-intervention rate in the DA stent group 
was observed in both studies43,44. DA stenting appears to be a 
feasible strategy for selected cases.
Alternatively, palliative balloon dilation of the pulmonary 
annulus can be used to increase oxygen saturation and pro-
mote growth of the pulmonary vasculature and as bridge to later 
complete repair in selected patients45,46. Whether this strategy 
ultimately reduces TAP use or improves long-term outcomes 
remains controversial45,46.
Similarly, RVOT stenting can be used as a palliative strategy or 
bridge to repair in neonatal life47,48. Experience with this strat-
egy is still relatively limited but it has been demonstrated to 
be a relatively safe procedure promoting growth of the pulmo-
nary arteries as a bridge to repair48–50. Quandt et al. compared 
medium-term outcomes of RVOT stent with systemic-to- 
pulmonary shunt and found no difference in survival between 
strategies49. Intensive care and hospital stay duration and peri- 
operative complications were more favorable for the RVOT 
stenting group but the re-intervention rate was higher for this 
group49. The most common re-interventions in this group were 
re-stenting and re-ballooning. (Re)shunt surgery or early 
complete repair was less common in this group compared with 
patients who underwent primary mBT. Comparisons between 
neonatal repair and RVOT stenting have shown compara-
ble short-term and long-term outcomes51,52. During 10 years 
of follow-up, Wilder et al. demonstrated a similar increased 
rate of catheter-based re-interventions in the RVOT stent group 
compared with neonatal repair52. More studies are needed 
to determine the best strategy for the patient group requir-
ing early intervention. Management strategies likely need to be 
individualized for optimal outcome.
Overall survival
Overall survival following ToF repair has significantly improved 
in recent eras. Figure 3 outlines survival in several large stud-
ies published within the last two decades, and follow-up was 
up to 40 years for older cohorts12,53–65. Early mortality has 
significantly decreased in more recent eras. European and 
American congenital cardiothoracic surgery registries have 
reported a peri-operative mortality below 3% in recent years66–68. 
Peri-operative outcomes are determined largely by the sever-
ity of the ToF described by, for example, the pre-operative size 
of the pulmonary valve and pulmonary arteries, RV-PA pres-
sure gradient, and oxygen saturation61,69–71. Patients with repair 
including TAP have higher peri-operative mortality66. As 
most centers consider a TAP only when the pulmonary annu-
lus z-score is lower than −2 or −3, this in part reflects more 
severe ToF21,72. Furthermore, co-morbidities, such as coronary 
abnormalities, prematurity, small body size–associated lesions, 
and genetic abnormalities, have been associated with increased 
peri-operative mortality61,69–71,73.
Mortality rates at medium-term follow-up have not changed 
much across the different surgical eras (Figure 3)65. Survival at 
30 years ranges from 68.5% to 90.5%54,57,58,62–65. Long-term (20 
to 30 years) survival from large cohorts of patients operated on 
with more recent surgical modifications of ToF repair (for 
example, valve-sparing and valve-replacing techniques) is still 
lacking. Important factors determining long-term outcome 
are residual RVOTO and severity of PR54.
Survival into adulthood is currently expected following ToF 
repair, leading to a growing population of adults with cor-
rected ToF who require lifelong specialized medical care74–77. 
Re-interventions are common in these patients. Cuypers et al. 
found that 44% of patients underwent at least one surgi-
cal or catheter re-intervention after 35 years of follow-up63. 
D’Udekem et al. found that 24 ± 5% of patients underwent 
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re-operation after 30 years of follow-up64. Following transa-
trial transpulmonary repair, lower rates of re-interventions 
have been reported. Luijten et al.12 found a 80% freedom of re- 
intervention and death after 10 years and D’Udekem et al.64 
found 75% freedom of re-operation after 25 years. A small 
case-control study found a lower pulmonary valve replacement 
(PVR) rate following transatrial repair compared with trans-
ventricular repair. The use of a TAP is associated with a higher 
re-intervention rate12,54, as is severity of ToF at repair56,65. 
Specific indications for re-interventions will be discussed later in 
this article.
Residual problems and re-interventions
Residual right ventricle outflow tract obstruction
Residual RVOTO is common following repair and results in 
residual or progressive concentric hypertrophy of the RV. Data 
obtained from the INDICATOR study suggest that RV hyper-
trophy, due to increased mass-to-volume ratio, is a more impor-
tant long-term risk factor for ventricular tachycardia (VT) and 
death than severity of RV dilation (RV end-diastolic volume 
index)78. Current guidelines provide clear indications for 
re-intervention for residual RVOTO (Table 1)75–77. Balloon 
valvuloplasty or PVR can be performed for valvular pulmo-
nary stenosis (PS). PA branch stenosis can be safely relieved by 
balloon dilation, stenting, or PA reconstruction79. In several large 
studies, 1% to 7% of patients have undergone PA dilation or stent-
ing at long-term follow-up (median of 5.8 to 36 years)61,63,64,80,81. 
Surgical relief of the RVOT and PA plasties were performed 
in 1% to 5% of patients at long-term follow-up61,63,80,81.
Pulmonary regurgitation
PR is very common at medium- to long-term follow-up. Five 
to ten years after repair, 40% to 85% of patients have moder-
ate to severe PR53,73,82–84. PR induces RV volume overload of 
the RV with often progressive RV dilation, which may include 
the development of tricuspid regurgitation (TR) and RV dys-
function. It is often accompanied by prolongation of the QRS 
complex, and RV dyssynchrony could contribute to the 
progression of dysfunction85–87. There generally is a long period 
in a compensated state, during which RV function is main-
tained. In some patients, these compensatory mechanisms fail, 
leading to progressive RV dysfunction85,86. The mechanisms of 
RV adaptation and remodeling, as well as the molecular events 
contributing to the transition from a compensated to a decom-
pensated state, are still poorly understood. Timely restora-
tion of pulmonary valve competence is considered to halt the 
progressive adverse RV remodeling resulting in RV dysfunction 
seen in chronic PR. 
Figure 3. Survival following tetralogy of Fallot (ToF) repair. Each colored line represents a single study, and dots represent Kaplan–Meier 
survival estimates at different time points12,53–65. Ninety-five percent confidence intervals, where published, are shown in vertical lines. Lines 
are colored according to surgical era.
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Table 1. Indications for pulmonary valve replacement in current guidelines.
European Society of Cardiology 
(2010)75
American College of Cardiology/American Heart 
Association (2008)73
Canadian Cardiovascular 
Society (2009)74
Class I Symptomatic patients with severe PR 
and/or 
PS (RV systolic pressure >60 mm Hg, 
TR velocity >3.5 m/s)
Severe PR 
and 
Symptoms or decreased exercise tolerance
Class IIa Severe PR or PS (or both) 
and either:
Severe PR 
and either:
Free PR 
and either:
RV size Moderate to severe RV enlargement EDVi 170 mL/m2
Progression of 
RV size
Progressive RV dilation Progressive RV dilation
RV function Progressive RV dysfunction Moderate to severe RV dysfunction Moderate to severe RV 
dysfunction
TR Progressive TR, at least moderate Moderate to severe TR Important TR
PS PS RV systolic pressure greater than 
80 mm Hg, TR velocity 4.3 m/s
Peak instantaneous echocardiography gradient 
greater than 50 mm Hg 
or 
RV/LV pressure ratio greater than 0.7 
or 
Residual RVOT obstruction (valvular or subvalvular) 
with progressive and/or severe dilatation of the RV 
with dysfunction
RV pressure at least 2/3 
systemic pressure
Exercise 
capacity
Decrease in objective exercise 
capacity
Symptoms such as 
deteriorating exercise 
performance
Arrhythmia Sustained atrial or ventricular 
arrhythmia
Symptomatic or sustained atrial and/or ventricular 
arrhythmias
Atrial or ventricular 
arrhythmia
EDVi, end-diastolic volume index; LV, left ventricle; PR, pulmonary regurgitation; PS, pulmonary stenosis; RV, right ventricle; RVOT, right ventricle outflow tract; 
TR, tricuspid regurgitation.
Thirty-five years after ToF repair, PVR will have been per-
formed in about 40% of patients63,65,88. Staged repair and TAP 
are risk factors for late PVR12,54,63,80, whereas mild residual PS 
seems to reduce risk89. As more patients with ToF survive into 
adulthood, PVRs are increasingly being performed90.
PVR is effective in decreasing RV volumes, reducing TR, 
decreasing QRS duration, increasing left ventricle (LV) 
ejection fraction (EF), and improving functional status91,92. It 
should be noted that no improvement in survival following PVR 
compared with medical management has been demonstrated 
to date93,94.
Homograft or bioprosthetic valves are currently the preferred 
valves for PVR95. The current 10-year re-PVR–free survival 
of ToF patients undergoing homograft PVR ranges from 
74% to 89%95,96.
Tissue-engineered valves with a non-synthetic and non- 
immunogenic surface have the potential to provide lifelong valve 
replacement97. In situ tissue engineering techniques, in which 
a decellularized “starter scaffold” of polymers can be used 
to provide shape and structure to the valve, are of particular 
interest. This scaffold is infiltrated by endogenous cells to pro-
vide a regenerating functional valve. As the scaffold would be 
non-immunogenic, this could provide a relatively cheap “off 
the shelf” valve. Current studies evaluating tissue-engineered 
valves in animals and humans show promising early results98.
Several transcatheter PVR strategies have been developed 
and are increasingly used in a clinical (trial) setting99. How-
ever, clinical experience compared with (surgical) homograft 
PVR is limited99. Procedural success of transcatheter PVR is 
generally good (>95%)100. The hazard rate for re-intervention 
following transcatheter PVR ranges from 0.4% to 5.9% per 
patient-year100. However, high rates of infective endocardi-
tis during follow-up have been described101. Recent results 
from the MELODY Registry estimate the infective endocardi-
tis risk to be 2.3% per patient-year102. In comparison, the infec-
tive endocarditis risk in surgical PVR has been estimated to be 
0.3% per patient-year103. Transcatheter PVR has been shown 
to increase exercise capacity and quality of life 6 months 
after the procedure104,105. Direct comparisons with surgical 
PVR are still lacking.
Page 6 of 15
F1000Research 2019, 8(F1000 Faculty Rev):1530 Last updated: 29 AUG 2019
Arrhythmia
Ventricular tachycardia. VT is a common arrhythmia in the 
repaired ToF population. Cuypers et al. reported a 5% cumu-
lative incidence of sustained VT after a median of 35 years 
after ToF repair63 and these figures are similar to those of most 
reports58,106. However, cumulative incidences of up to 15% have 
been reported in some adult populations107. Predictors of sustained 
VT include higher age, number of prior cardiac surgeries, pres-
ence of a TAP, LV diastolic dysfunction, and QRS width63,106–108. 
Most guidelines recommend implantable cardioverter defibril-
lators (ICDs) for patients who have had sustained VT or car-
diac arrest76,77. ICDs are also employed for primary prevention, 
although selecting high-risk patients who would benefit 
from ICD implantation remains challenging76,77. Pacemaker 
and ICD prevalences in adult ToF populations both range from 
5% to 10%63,107,109.
Electrophysiological studies can help to determine the underly-
ing substrate, and radiofrequency ablation can be performed. 
Ablation of monomorphic VT substrates has excellent short-
term outcomes with recurrent VT in 18% of patients after a 
mean follow-up of 34 months110. Another study found a similar 
recurrence rate (19%) 10 years after ablation111.
Supraventricular tachycardia. The prevalence or cumula-
tive incidence of supraventricular tachycardia (SVT) in adult 
patients ranges from 4% to 20%107–109,112. In the first 10 to 15 
years following ToF repair, SVT is relatively uncommon but 
the incidence rises steadily after this period107. Intra-atrial re- 
entrant tachycardia, typically involving the right atrium, is 
the most common type of SVT in patients with ToF107. Two 
large studies found that SVT was an independent predictor of 
death or VT78,108. Few studies have assessed the efficacy of 
ablation of atrial arrhythmias in corrected ToF, and long-term 
follow-up is lacking113–115.
Aortopathy
Dilation of the aorta is seen in 12% to 24% of adult patients 
with ToF116–118. In patients with aortic dilation, aortic root size 
seems to progressively increase over a period of years. Aortic 
dissection following ToF appears to be a rare complication119. 
A population-based study in Texas demonstrated no increased 
risk for thoracic aortic dissection for patients with ToF com-
pared with the general population119. However, progressive aor-
tic root dilation can lead to malcoaptation of the aortic valve 
and aortic regurgitation. Furthermore, the elasticity of the 
dilated aortic root was shown to be reduced in patients with 
ToF, possibly hampering circulatory function120. The impor-
tance of aortopathy in circulatory function and mortality 
remains incompletely understood.
Knowledge gaps
Right ventricular adaptation and remodeling
The mechanisms of RV adaptation and remodeling in response 
to chronic RV volume overload, resulting from PR, are poorly 
understood121. In young pig models, chronic PR affects biv-
entricular systolic function, RV myocardial contractility, and 
LV diastolic performance122. Histopathology of several animal 
models displays early hypertrophy of the chronically volume-
loaded RV and, in a later stage, myocardial fibrosis121. The 
molecular responses to increased volume or pressure load-
ing of the RV are different from those in the LV121,123–125. In 
a pig model of repaired ToF with induced PR, PS, and an 
RVOT scar, RV hypertrophy and dilation were found after 
23 weeks. The myocardium was characterized by increased 
collagen deposition, leading to decreased impulse conduc-
tion velocity and dispersion126. Similar findings were found 
in the LV, despite preserved LV function at this stage. This 
demonstrates biventricular adverse effects are present early in the 
adverse remodeling process127.
Basic research into RV remodeling has focused mainly on the 
response to increased pressure loading rather than the pre-
dominantly volume-loaded RV as seen in PR124,125. Volume 
loading and pressure loading increase myocardial metabolic 
demand. This metabolic stress induces an increased amount of 
reactive oxygen species. Compensatory anti-oxidant production in 
the RV is impaired compared with the LV125. This might imply that 
the RV is more vulnerable to oxidative stress, as seen in abnormal 
loading conditions.
In volume-loaded RV mouse models, a clinical course simi-
lar to RV dysfunction with volume-loaded RV in humans is 
observed. RV function is maintained during a compensated phase, 
followed by RV dysfunction128. Gene expression patterns of 
the cardiomyocyte in the compensated state differ from those 
of healthy controls. Several molecular pathways, such as trans-
forming growth factor beta (TGF-β) signaling, p53 signaling, 
and cytoskeleton-related pathways, are downregulated in the 
early compensated state but show late upregulation as the RV 
progressively remodels128. However, the exact cellular and 
molecular mechanisms of transition from a compensated to 
a decompensated state of the volume-loaded RV have not 
been fully elucidated125,129.
Assessing the right ventricle in patients with tetralogy of 
Fallot
Our limited understanding of the pathophysiology of RV fail-
ure hampers our ability to adequately detect failure in the 
early stages in clinical practice. Imaging techniques are used 
to assess the RV and follow patients serially, aiming to detect 
early changes in biventricular size and performance. Cardiovas-
cular magnetic resonance (CMR) imaging is routinely used to 
reliably quantify RV volumes and function, wall mass, and 
PR130. Adverse clinical events have been related to larger RV 
volumes, PR severity, biventricular EF, and mass-to-volume 
ratio78,131,132. Increased RV volumes, most commonly end-diastolic 
volume index (EDVi), have been considered a sign of pro-
longed high PR burden and thus a predictor of RV dysfunction. 
However, exercise capacity can be preserved even in severely 
dilated ventricles, demonstrating that compensatory mechanisms 
can still be adequate to maintain performance of large RVs133. 
In the INDICATOR cohort, increased RV wall mass-to-volume 
ratio, among other factors, was found to be an independent 
predictor of VT and all-cause mortality, whereas RV EDV and 
end-systolic volume were not predictive of the end-points78. 
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RV hypertrophy could be a more sensitive marker of pending 
dysfunction than EDV, although this might be particularly true 
for patients with residual PS.
Regional myocardial performance and mechanical synchrony 
can be assessed by strain imaging studies. Global circumferen-
tial or longitudinal strain has been used to assess RV function. 
Under normal circumstances, the RV ejects mainly by longi-
tudinal shortening while, with increased RV pressure loading, 
circumferential contraction is increased134. The predictive value 
of global longitudinal or circumferential strain in ToF is still 
uncertain: Orwat et al. found that RV global longitudinal strain 
assessed by CMR was a superior independent predictor for 
death, cardiac arrest, or VT compared with RV volumes135. 
RV global circumferential strain was not predictive of out-
come in that study135. Diller et al. found a similar relation for LV 
global longitudinal strain assessed by echocardiography136.
Mechanical dyssynchrony has been demonstrated to relate 
to prolonged or fragmented (QRS complex containing addi-
tional spikes without bundle branch block) QRS complexes137. 
The contributions of this mechano-electrical interaction to RV 
function remain uncertain, as studies assessing mechanical 
dyssynchrony report conflicting results135,136,138–141. RV circum-
ferential dyssynchrony was shown to negatively predict exer-
cise capacity in one study140. This association has not been 
confirmed in other studies138,141. Cardiac resynchronization 
therapy is increasingly used in ToF. A recent study found that 
12 out of 15 adult patients with ToF had an improved NYHA 
(New York Heart Association) class or LV function after 
2.6 years (median) of cardiac resynchronization therapy142. 
Procedural success was high and adverse events were rare.
Right ventricular interactions in tetralogy of Fallot
Atrio-ventricular interactions. Diastolic function after ToF 
repair is a determinant of the amount of PR. In some patients, 
end-diastolic forward flow (EDFF) in the main PA during 
right atrial contraction can be observed143. This is considered a 
sign of “restrictive RV physiology” as the non-compliant RV 
acts as a conduit during atrial contraction as RV diastolic pres-
sure exceeds PA diastolic pressure144,145. Restrictive physiology 
could limit the amount of PR as elevated diastolic RV pressure 
reduces the amount of PR. A recent study found no relationship 
between the presence of EDFF and other markers of diastolic 
dysfunction (that is, RV hypertrophy, atrial dilatation, reduced 
stroke volume, or reduced PR)146. Different mechanisms, 
such as pulmonary arterial capacitance and atrial function147, 
may play significant roles in the occurrence of EDFF. Lui-
jnenburg et al. found that bi-atrial function, but not diastolic 
ventricular function, differed between patients with EDFF and 
those without it147. In that study, abnormal atrial function was 
related to worse exercise capacity and higher N-terminal pro 
brain natriuretic peptide (NT-proBNP). Kutty et al. found 
that right atrial longitudinal strain predicted RV performance 
but not exercise capacity148.
The effect of EDFF on circulatory function is controversial. 
Studies found conflicting results regarding the relationship 
between EDFF and the amount of PR143,144,146, exercise 
capacity144–147, and EDV144–147. The presence of EDFF might have 
a different etiology and clinical importance early versus late 
after repair or in severely dilated versus non-dilated ventricles.
Ventriculo-arterial interactions. Adequate atrio-ventricular 
coupling and ventriculo-arterial (VA) coupling are required 
for an energetically efficient transfer of blood through the 
right heart. VA coupling has not been studied extensively in 
ToF. Latus et al. assessed VA coupling as the relationship 
between pulmonary arterial elastance and ventricular end-
systolic elastance in adult patients with ToF by using CMR and 
catheter-derived measurements both in resting conditions 
and during dobutamine stress149. VA coupling was impaired 
during resting conditions. EF and load-independent parameters 
of RV contractility increased during dobutamine stress. Pulmo-
nary arterial elastance increased accordingly and the impaired 
VA coupling that resulted during dobutamine stress was similar to 
that under resting conditions.
Interventricular interactions. Interactions between the RV and 
LV have been extensively described. The LV and RV have com-
mon myocardial fibers, the interventricular septum, the anatomic 
space confined by the pericardium, and a common neurohu-
moral system150. Not unexpectedly, the effects of chronic PR 
are not limited to the RV, although the mechanisms of this 
ventriculo–ventriculo interaction in chronic PR remain poorly 
understood. A linear correlation between LV and RV EF has 
been described150,151. Severe RV dilation causes abnormal 
diastolic septal positioning, influencing LV filling152. The role 
of the LV in outcomes in ToF is increasingly appreciated, as 
LV function has been associated with increased mortality and 
increased risk of VT136,153. In the INDICATOR registry, LV EF 
was one of three independent predictors of mortality and 
VT154. Geva et al. found that LV EF, independent of RV param-
eters, predicted poor functional status151. Remarkably, parameters 
of LV function are not considered in current guidelines 
for the timing of PVR (Table 1).
Drug therapy for right ventricular failure
Pharmacotherapy is important in the treatment of LV failure and 
improves outcomes. However, the effects of the use of heart fail-
ure medication for RV failure have been disappointing155–157. 
In patients after ToF repair, RAAS (renin–angiotensin– 
aldosterone system) inhibitors do not appear to influence RV 
EF or exercise capacity158. In a randomized controlled trial of 
33 patients with ToF, beta blockers showed no beneficial effects 
after 6 months of treatment and an increase in NT-proBNP 
was noted159. Increasing our understanding of the pathophysi-
ology of RV failure might elucidate new targets for medical 
treatment unique to the RV.
Current guidelines on the timing of pulmonary valve 
replacement
Restoring pulmonary valve function before irreversible RV 
dysfunction occurs could be important to prevent RV failure. 
However, the durability of currently used pulmonary prosthetic 
valves is limited. Therefore, the timing of PVR always is a 
Page 8 of 15
F1000Research 2019, 8(F1000 Faculty Rev):1530 Last updated: 29 AUG 2019
compromise: It should be timed early enough to prevent irrevers-
ible adverse remodeling but late enough to limit the number of 
re-interventions. Because of the difficulties in assessing RV 
function, predicting decline in RV function is difficult, and 
the optimal timing of PVR is controversial. Guidelines by the 
European Society of Cardiology, the Canadian Cardiovascu-
lar Society (CCS), and the American College of Cardiology/
American Heart Association provide some recommendations 
on indications for performing PVR75–77. These indications are 
summarized in Table 1.
Indications differ between guidelines and have several limita-
tions. Most guidelines do not provide specific cutoff points since 
these are statistical constructs that do not work for individual 
patients. The 2009 CCS guideline provides an absolute cutoff 
value for EDVi but does not take into account the considerable 
differences in normal (indexed) RV volumes between genders 
and age160. End-systolic volume index and RV mass-to-volume 
ratio have been proposed as superior predictors compared with 
EDV78,161. Progressive RV dilation is considered an indica-
tion for PVR, but there is no consensus on what too much 
progression is162–165. Longitudinal changes in RV size and 
function following ToF repair have been reported in several 
studies166–173. RV volumes increase non-linearly and seem to 
stabilize in adolescence. These factors need to be taken into 
account when assessing progressive RV dilation.
Furthermore, the recommendations in current guidelines are 
often based on long-term outcomes of studies in patients who 
have been operated at a much older age than has been the prac-
tice in the past 20 years. This warrants caution when extrapolating 
these results to current adolescent or younger patients.
Careful interpretation of current guidelines seems to be justi-
fied. Individual patient parameters and views should always 
be taken into consideration. In clinical practice, an approach 
using information from different sources, including history, 
physical examination, electrocardiogram, imaging techniques, 
exercise testing, and blood biomarkers, may be most useful174.
Conclusions
ToF can be repaired with low short-term and long-term mor-
tality. This has caused a demographic shift such that many 
patients survive well into adulthood. Long-term follow-up of 
older cohorts has shown the detrimental effects of PR in the 
long-term. However, residual lesions cause significant morbid-
ity. Surgical modifications to preserve pulmonary valve function, 
such as the transatrial (and transpulmonary) approaches and 
restricted use of TAPs, have been widely adopted. Despite 
improvements in morbidity, follow-up duration for these tech-
niques is probably too limited to demonstrate a survival 
benefit.
Our limited understanding of RV adaptation and the patho-
physiology of RV heart failure hampers the ability to detect 
failure in early stages in clinical practice and to predict future 
decline of RV function. While a large proportion of adult ToF 
survivors require one or multiple PVRs in their lifetimes, 
selecting optimal candidates and optimal timing for PVR 
remains challenging. Increasing our understanding of RV fail-
ure seems key to answer these difficult questions. This might 
provide treatment options to attain optimal long-term health 
outcomes for patients with ToF.
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